Cutting-edge biotechnologies are emerging in gene therapy and protein manufacturing. Cirrus Therapeutics launched with $11 million to develop gene therapies targeting eye aging diseases by modulating immune functions. Mercury Bio announced promising preclinical data for its yeast-derived extracellular vesicles delivering proteins across the blood-brain barrier, a critical hurdle for neurological treatments. Meanwhile, researchers at the University of Warwick engineered microbial cell factories for longer-lasting and enhanced protein production without antibiotics, advancing sustainable biomanufacturing processes.